IL13RA2 and glioblastoma: In fact, IL13Rα2 expression correlates moderately with the mesenchymal signature [100], a subtype of GBM associated with greater proliferation, tumorigenicity and resistance to conventional chemoradiotherapy as compared to other subtypes [102,103].